GuidelineMMWR. Morbidity and mortality weekly report2018
Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel.
Guideline in MMWR. Morbidity and mortality weekly report, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2019.MMWR. Morbidity and mortality weekly report · 2019Guideline
- Travel vaccination in senior travelers: current evidence, challenges, and prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Targeting the 3C Protease of Hepatitis A Virus Subgenotype IB: Virtual Screening and Identification of Potent Lead Candidates.Microorganisms · 2026Article
- Traveling with chronic viral hepatitis.Tropical diseases, travel medicine and vaccines · 2026Review
- Review of Infections in Immunocompromised Travellers: Epidemiology, Infection Prevention and Management.Microorganisms · 2026Review
- Prevalence of viral hepatitis A and C in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.The Korean journal of internal medicine · 2026Article
- Immunogenicity assessment of Hepatitis A-VP1 and Hepatitis B surface antigen (HBsAg) fusion protein: a novel bivalent vaccine candidate.Iranian journal of microbiology · 2025Article
- Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.Biological procedures online · 2025Review
- Hepato-selective dihydroquinolizinones active against hepatitis A virus in vitro and in vivo.Antiviral research · 2025Article
- Hepatitis A beyond childhood causing diagnostic and therapeutic challenges in Addis Ababa, Ethiopia.PloS one · 2025Article
- Review
- Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial.EClinicalMedicine · 2023Article
- Review
- Endemicity change of hepatitis A infection necessitates vaccination in food handlers: An Indian perspective.Human vaccines & immunotherapeutics · 2022Review
- Viral hepatitis in pregnancy.Journal of viral hepatitis · 2022Review
- Rare Diagnostic and Clinical Manifestations in an Acute Hepatitis A Infection: A Case Report.Cureus · 2022Article
- Viral hepatitis: Past, present, and future.World journal of gastroenterology · 2022Review
- Acute hepatitis A in international travellers: a GeoSentinel analysis, 2008-2020.Journal of travel medicine · 2022Article
- Role of bioactive compounds in the treatment of hepatitis: A review.Frontiers in pharmacology · 2022Review
- Screening of Hepatitis A and B Seropositivity among Turkish Healthcare Providers Admitted to Occupational Health Services.International journal of clinical practice · 2022Observational
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postexposure prophylaxis (PEP) with hepatitis A (HepA) vaccine or immune globulin (IG) effectively prevents infection with hepatitis A virus (HAV) when administered within 2 weeks of exposure. Preexposure prophylaxis against HAV infection through the administration of HepA vaccine or IG provides protection for unvaccinated persons traveling to or working in countries that have high or intermediate HAV endemicity. The Advisory Committee on Immunization Practices (ACIP) Hepatitis Vaccines Work Group conducted a systematic review of the evidence for administering vaccine for PEP to persons aged >40 years and reviewed the HepA vaccine efficacy and safety in infants and the benefits of protection against HAV before international travel. The February 21, 2018, ACIP recommendations update and supersede previous ACIP recommendations for HepA vaccine for PEP and for international travel. Current recommendations include that HepA vaccine should be administered to all persons aged ≥12 months for PEP. In addition to HepA vaccine, IG may be administered to persons aged >40 years depending on the provider's risk assessment. ACIP also recommended that HepA vaccine be administered to infants aged 6-11 months traveling outside the United States when protection against HAV is recommended. The travel-related dose for infants aged 6-11 months should not be counted toward the routine 2-dose series. The dosage of IG has been updated where applicable (0.1 mL/kg). HepA vaccine for PEP provides advantages over IG, including induction of active immunity, longer duration of protection, ease of administration, and greater acceptability and availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.